Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention

Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention

Treatment of schizophrenia (SCZ) historically relies on the use of antipsychotic drugs to treat psychosis, with all of the currently available antipsychotics acting through the antagonism of dopamine D2 receptors. Although antipsychotics reduce psychotic symptoms in many patients, they induce numero...

Full description

Bibliographic Details
Main Authors:	Felipe V. Gomes, Anthony A. Grace
Format:	Article
Language:	English
Published:	MDPI AG 2021-04-01
Series:	International Journal of Molecular Sciences
Subjects:	dopamine psychosis antipsychotics hippocampus parvalbumin glutamate
Online Access:	https://www.mdpi.com/1422-0067/22/9/4467

Similar Items

Dopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands and Concepts in Schizophrenia
by: Jean Claude Martel, et al.
Published: (2020-07-01)

α5-GABAA Receptor Modulation Reverses Behavioral and Neurophysiological Correlates of Psychosis in Rats with Ventral Hippocampal Alzheimer’s Disease-like Pathology
by: Nicole E. Eassa, et al.
Published: (2023-07-01)

Philip Seeman and Dopamine and Schizophrenia
by: Mary V Seeman
Published: (2021-09-01)

Dopamine dilemma: case report of treating psychosis in patient with retinitis pigmentosa
by: Haitham Salem, et al.
Published: (2019-01-01)

Association of SLC6A3 variants with treatment-resistant schizophrenia: a genetic association study of dopamine-related genes in schizophrenia
by: Masanobu Kogure, et al.
Published: (2024-02-01)

Glutamate neurocircuitry: theoretical underpinnings in schizophrenia
by: Thomas L Schwartz, et al.
Published: (2012-11-01)

Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
by: Davide Amato, et al.
Published: (2019-05-01)

Canonical and Non-Canonical Antipsychotics’ Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia
by: Andrea de Bartolomeis, et al.
Published: (2023-03-01)

Dysregulation of Midbrain Dopamine System and the Pathophysiology of Schizophrenia
by: Susan F. Sonnenschein, et al.
Published: (2020-06-01)

Are CB2 Receptors a New Target for Schizophrenia Treatment?
by: Isadora L. Cortez, et al.
Published: (2020-10-01)

Dopamine, Cognitive Function, and Gamma Oscillations: Role of D4 Receptors
by: Katrina Eileen Furth, et al.
Published: (2013-07-01)

Structural and Functional Deviations of the Hippocampus in Schizophrenia and Schizophrenia Animal Models
by: David Wegrzyn, et al.
Published: (2022-05-01)

Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics
by: Andrea de Bartolomeis, et al.
Published: (2022-06-01)

Oxidative Stress and the Pathophysiology and Symptom Profile of Schizophrenia Spectrum Disorders
by: Alex J. Murray, et al.
Published: (2021-07-01)

The Effects of Antipsychotics on the Synaptic Plasticity Gene <i>Homer1a</i> Depend on a Combination of Their Receptor Profile, Dose, Duration of Treatment, and Brain Regions Targeted
by: Felice Iasevoli, et al.
Published: (2020-08-01)

Insights into the Mechanism of Action of Antipsychotic Drugs Derived from Animal Models: Standard of Care versus Novel Targets
by: Anthony A. Grace, et al.
Published: (2023-08-01)

Epigenetic Targets in Schizophrenia Development and Therapy
by: Agnieszka Wawrzczak-Bargieła, et al.
Published: (2023-03-01)

The relationship between combined antipsychotic use and clinical features in schizophrenia spectrum patients treated in inpatient ward: A retrospective study
by: U. Baklaci
Published: (2021-04-01)

Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia
by: U. Sauerzopf, et al.
Published: (2021-01-01)

Aberrant Dopamine System Function in the Ferrous Amyloid Buthionine (FAB) Rat Model of Alzheimer’s Disease
by: Stephanie M. Perez, et al.
Published: (2023-04-01)

New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists
by: Peng A, et al.
Published: (2024-03-01)

Using animal models for the studies of schizophrenia and depression: The value of translational models for treatment and prevention
by: Daniela L. Uliana, et al.
Published: (2022-08-01)

Assessing NH300094, a novel dopamine and serotonin receptor modulator with cognitive enhancement property for treating schizophrenia
by: Zijin Feng, et al.
Published: (2024-01-01)

Mapping alterations in the local synchrony of the cerebral cortex in schizophrenia
by: Jesus Pujol, et al.
Published: (2023-01-01)

Six Decades of Dopamine Hypothesis: Is Aryl Hydrocarbon Receptor the New D2?
by: Adonis Sfera
Published: (2023-08-01)

The Role of Cytokines in the Pathogenesis of Schizophrenia
by: Bartosz Dawidowski, et al.
Published: (2021-08-01)

Schizophrenia : Current concepts in aetiology
by: P S Bhat, et al.
Published: (2014-01-01)

The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue.
by: Ralf eBrisch, et al.
Published: (2014-05-01)

Dopamine D3 receptors inhibit hippocampal gamma oscillations by disturbing CA3 pyramidal cell firing synchrony
by: Clément E. Lemercier, et al.
Published: (2016-01-01)

Pharmaco-Magnetic Resonance as a Tool for Monitoring the Medication-Related Effects in the Brain May Provide Potential Biomarkers for Psychotic Disorders
by: Katrin Aryutova, et al.
Published: (2021-08-01)

Synapse Type-Dependent Expression of Calcium-Permeable AMPA Receptors
by: Txomin Lalanne, et al.
Published: (2018-10-01)

Relationship between antipsychotic medication and aggressive events in patients with a psychotic disorder hospitalized for treatment
by: Georgia Tseligkaridou, et al.
Published: (2023-03-01)

The impact of pimavanserin on psychotic phenotypes and tau phosphorylation in the P301L/COMT– and rTg(P301L)4510 mouse models of Alzheimer's disease
by: Heidy Jimenez, et al.
Published: (2022-01-01)

Activation of Dopamine 4 Receptor Subtype Enhances Gamma Oscillations in Hippocampal Slices of Aged Mice
by: Yuan Wang, et al.
Published: (2022-03-01)

Dopamine and Dopamine-Related Ligands Can Bind Not Only to Dopamine Receptors
by: Jaromir Myslivecek
Published: (2022-04-01)

How do participants in clinical trials compare with other patients with schizophrenia?
by: Robert Freudenthal, et al.
Published: (2021-06-01)

Ventral midbrain NMDA receptor blockade: from enhanced reward and dopamine inactivation.
by: Giovanni Hernandez, et al.
Published: (2016-08-01)

Antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability
by: Rachael K. Blackman, et al.
Published: (2022-03-01)

New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
by: Albert C. Yang, et al.
Published: (2017-08-01)

The Role of Dopamine D3 Receptors, Dysbindin, and Their Functional Interaction in the Expression of Key Genes for Neuroplasticity and Neuroinflammation in the Mouse Brain
by: Veronica Rivi, et al.
Published: (2023-05-01)